Insufficient scRNA-seq data for expression of CD274 at single-cell level.
Insufficient scRNA-seq data for expression of CD274 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 441.42 | 653 / 653 | 92% | 12.78 | 556 / 605 |
lung | 100% | 2947.25 | 578 / 578 | 89% | 15.58 | 1028 / 1155 |
kidney | 100% | 373.57 | 89 / 89 | 83% | 6.54 | 748 / 901 |
esophagus | 95% | 263.46 | 1366 / 1445 | 85% | 7.05 | 155 / 183 |
breast | 95% | 281.43 | 438 / 459 | 71% | 4.39 | 799 / 1118 |
uterus | 93% | 314.08 | 158 / 170 | 73% | 12.30 | 333 / 459 |
pancreas | 91% | 185.30 | 299 / 328 | 74% | 3.87 | 131 / 178 |
bladder | 95% | 190.48 | 20 / 21 | 59% | 8.43 | 299 / 504 |
stomach | 84% | 188.35 | 301 / 359 | 61% | 6.68 | 175 / 286 |
intestine | 86% | 222.79 | 832 / 966 | 58% | 4.66 | 307 / 527 |
adrenal gland | 82% | 175.78 | 211 / 258 | 60% | 5.05 | 139 / 230 |
ovary | 90% | 185.83 | 162 / 180 | 41% | 1.69 | 177 / 430 |
skin | 63% | 152.11 | 1136 / 1809 | 65% | 6.49 | 306 / 472 |
prostate | 96% | 331.54 | 236 / 245 | 28% | 0.89 | 141 / 502 |
brain | 70% | 163.69 | 1840 / 2642 | 50% | 3.22 | 353 / 705 |
spleen | 100% | 1768.25 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 421.12 | 1193 / 1204 | 0% | 0 | 0 / 0 |
liver | 79% | 248.92 | 178 / 226 | 18% | 1.14 | 75 / 406 |
heart | 97% | 816.59 | 836 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 18.21 | 42 / 45 |
blood vessel | 91% | 307.86 | 1215 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 31.11 | 26 / 29 |
peripheral blood | 84% | 2103.03 | 782 / 929 | 0% | 0 | 0 / 0 |
muscle | 79% | 189.46 | 632 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 28% | 1.45 | 22 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0035666 | Biological process | TRIF-dependent toll-like receptor signaling pathway |
GO_0042102 | Biological process | positive regulation of T cell proliferation |
GO_0002841 | Biological process | negative regulation of T cell mediated immune response to tumor cell |
GO_0034097 | Biological process | response to cytokine |
GO_0007165 | Biological process | signal transduction |
GO_0031295 | Biological process | T cell costimulation |
GO_0070232 | Biological process | regulation of T cell apoptotic process |
GO_0032733 | Biological process | positive regulation of interleukin-10 production |
GO_0032693 | Biological process | negative regulation of interleukin-10 production |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_1903556 | Biological process | negative regulation of tumor necrosis factor superfamily cytokine production |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0046007 | Biological process | negative regulation of activated T cell proliferation |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_1905404 | Biological process | positive regulation of activated CD8-positive, alpha-beta T cell apoptotic process |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_1905399 | Biological process | regulation of activated CD4-positive, alpha-beta T cell apoptotic process |
GO_0032689 | Biological process | negative regulation of type II interferon production |
GO_2000562 | Biological process | negative regulation of CD4-positive, alpha-beta T cell proliferation |
GO_0046006 | Biological process | regulation of activated T cell proliferation |
GO_2001186 | Biological process | negative regulation of CD8-positive, alpha-beta T cell activation |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0055038 | Cellular component | recycling endosome membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0005634 | Cellular component | nucleus |
GO_0048018 | Molecular function | receptor ligand activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CD274 |
Protein name | Programmed cell death 1 ligand 1 (PD-L1) (PDCD1 ligand 1) (Programmed death ligand 1) (hPD-L1) (B7 homolog 1) (B7-H1) (CD antigen CD274) |
Synonyms | B7H1 PDL1 PDCD1L1 PDCD1LG1 |
Description | FUNCTION: Plays a critical role in induction and maintenance of immune tolerance to self . As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response . Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) . Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis . .; FUNCTION: The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival . The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity). . |
Accessions | ENST00000381573.8 [Q9NZQ7-2] Q9NZQ7 ENST00000381577.4 [Q9NZQ7-1] |